NMN is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring with a ribose sugar and a phosphate group. The compound appears in cells across many organisms as an intermediate in the production of nicotinamide adenine dinucleotide, or NAD+. Because NMN sits close to NAD+ in metabolism, it has drawn interest in biochemistry and aging research. The molecule is not a dietary essential nutrient in the classical sense, and its presence in food is generally low and variable.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
Two enzymatic steps define the canonical route from nicotinamide to NAD+. Nicotinamide phosphoribosyltransferase, known as NAMPT, produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN adenylyltransferases, or NMNAT enzymes, then couple NMN with ATP to form NAD+. Whether intact NMN crosses cell membranes efficiently remains an active area of investigation; some studies propose direct transport, while others emphasize extracellular dephosphorylation to nicotinamide riboside followed by uptake. The relative contribution of each route likely depends on cell type, tissue, and experimental conditions.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
=== Intravenous fluids === In those with poor tissue perfusion, boluses of isotonic crystalloid solution should be given. In children with more than 10–20% TBSA (Total Body Surface Area) burns, and adults with more than 15% TBSA burns, formal fluid resuscitation and monitoring should follow. This should be begun pre-hospital if possible in those with burns greater than 25% TBSA. The Parkland formula can help determine the volume of intravenous fluids required over the first 24 hours. The formula is based on the affected individual's TBSA and weight. Half of the fluid is administered over the first 8 hours, and the remainder over the following 16 hours. The time is calculated from when the burn occurred, and not from the time that fluid resuscitation began. Children require additional maintenance fluid that includes glucose. Additionally, those with inhalation injuries require more fluid. While inadequate fluid resuscitation may cause problems, over-resuscitation can also be detrimental. The formulas are only a guide, with infusions ideally tailored to a urinary output of >30 mL/h in adults or >1mL/kg in children and mean arterial pressure greater than 60 mmHg. While lactated Ringer's solution is often used, there is no evidence that it is superior to normal saline. Crystalloid fluids appear just as good as colloid fluids, and as colloids are more expensive they are not recommended. Blood transfusions are rarely required. They are typically only recommended when the hemoglobin level falls below 60-80 g/L (6-8 g/dL) due to the associated risk of complications.
Governments have the primary public health mandate of ensuring safe food for all, however all actors in the food chain are responsible to ensure only safe food reaches the consumer, thus preventing foodborne illnesses. This is achieved through the implementation of strict hygiene rules and a public veterinary and phytosanitary service that monitors animal products throughout the food chain, from farming to delivery in shops and restaurants. This regulation includes:
Freeman also narrated The True Story of Glory Continues, a documentary about the 54th Massachusetts Infantry Regiment. In 1992, he appeared in Clint Eastwood's western Unforgiven, which won four Academy Awards including Best Picture. The film depicts William Munny (Eastwood), an aging outlaw and killer who takes on one more job with old friend Ned Logan (Freeman). Unforgiven was widely acclaimed, with one critic calling Freeman's performance "outstanding". Also in 1992 Freeman starred in the John G. Avildsen directed drama The Power of One acting opposite Stephen Dorf and John Gielgud in a loose adaptation of Bryce Courtenay's 1989 novel of the same name, in which he plays boxing coach Geel Piet. In 1993, Freeman made his directorial debut with the drama Bopha!, which tells the story of a black policeman (Danny Glover) during South Africa's apartheid era. Bopha! was well-received, in particular for Freeman's directing. Hal Hinson of The Washington Post wrote: "Freeman lays out the father-son dynamics with great skill and very little fuss. There's no hysteria in his approach; instead, he sticks to the facts, relying on his cast to provide the emotion. The result is a surprisingly powerful, insightful film." Kenneth Turan from Los Angeles Times also complimented Freeman's direction but thought the film was "more predictable than powerful". In 1994, Freeman portrayed Red, the redeemed convict in Frank Darabont's acclaimed drama The Shawshank Redemption, with co-star Tim Robbins. It is based on the 1982 Stephen King novella Rita Hayworth and the Shawshank Redemption.
Sources: en.wikipedia.org
Dyson joined the faculty at Cornell as a physics professor in 1951, though he still had no doctorate. In December 1952, Oppenheimer, the director of the Institute for Advanced Study in Princeton, New Jersey, offered Dyson a lifetime appointment at the institute, "for proving me wrong", in Oppenheimer's words. Dyson remained at the Institute until the end of his career. In 1957 he became a US citizen. From 1957 to 1961 Dyson worked on Project Orion, which proposed the possibility of space-flight using nuclear pulse propulsion. A prototype was demonstrated using conventional explosives, but the 1963 Partial Test Ban Treaty, in which Dyson was involved and which he supported, permitted only underground nuclear weapons testing, and the project was abandoned in 1965. In 1958 Dyson was a member of the design team under Edward Teller for TRIGA, a small, inherently safe nuclear reactor used throughout the world in hospitals and universities for the production of medical isotopes. In 1966, independently of Elliott H. Lieb and Walter Thirring, Dyson and Andrew Lenard published a paper proving that the Pauli exclusion principle plays the main role in the stability of matter. Hence it is not the electromagnetic repulsion between outer-shell orbital electrons that prevents two stacked wood blocks from coalescing into a single piece, but the exclusion principle applied to electrons and protons that generates the classical macroscopic normal force. In condensed matter physics, Dyson also analysed the phase transition of the Ising model in one dimension and spin waves.
=== Pharmacology === Preclinical and early clinical pharmacology studies characterized insulin icodec as a basal insulin analogue. The molecular modifications were intended to create an albumin-bound circulating depot, while preserving insulin receptor-mediated metabolic activity and limiting mitogenic activity relative to human insulin.
The melanocortins are a family of neuropeptide hormones which are the ligands of the melanocortin receptors. The melanocortin system consists of melanocortin receptors, ligands, and accessory proteins. The genes of the melanocortin system are found in chordates. Melanocortins were originally named so because their earliest known function was in melanogenesis. It is now known that the melanocortin system regulates diverse functions throughout the body, including inflammatory response, fibrosis, melanogenesis, steroidogenesis, energy homeostasis, sexual function, and exocrine gland function. There are four endogenous melanocortin agonists which are derived from post-transcriptional processing of the precursor molecule proopiomelanocortin (POMC). They are adrenocorticotropic hormone (ACTH), α-melanocyte stimulating hormone (MSH), β-MSH, and γ-MSH. In addition to agonists which activate melanocortin receptors, there are two antagonists which inhibit receptor activity, agouti-signaling protein (ASIP) and agouti-related protein (AgRP). Lastly, the ligand β-defensin 3 acts as a neutral melanocortin receptor antagonist.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
NMN is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis. It consists of nicotinamide attached to a ribose phosphate unit. Cells produce it through the salvage pathway.